[go: up one dir, main page]

RU2015148496A - 4-Phenylpyrrolidinone-2 derivative containing its composition with nootropic activity, a method for their preparation and a method for the treatment or prevention of disorders of the nerve system - Google Patents

4-Phenylpyrrolidinone-2 derivative containing its composition with nootropic activity, a method for their preparation and a method for the treatment or prevention of disorders of the nerve system Download PDF

Info

Publication number
RU2015148496A
RU2015148496A RU2015148496A RU2015148496A RU2015148496A RU 2015148496 A RU2015148496 A RU 2015148496A RU 2015148496 A RU2015148496 A RU 2015148496A RU 2015148496 A RU2015148496 A RU 2015148496A RU 2015148496 A RU2015148496 A RU 2015148496A
Authority
RU
Russia
Prior art keywords
composition
potassium taurate
disorders
nootropic activity
prevention
Prior art date
Application number
RU2015148496A
Other languages
Russian (ru)
Other versions
RU2611623C2 (en
Inventor
Вадим Витальевич Негребецкий
Евгения Петровна Крамарова
Александр Геннадьевич Шипов
Юрий Иванович Бауков
Татьяна Анатольевна Шмиголь
Нина Михайловна Киселева
Original Assignee
Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации filed Critical Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации
Priority to RU2015148496A priority Critical patent/RU2611623C2/en
Publication of RU2015148496A publication Critical patent/RU2015148496A/en
Application granted granted Critical
Publication of RU2611623C2 publication Critical patent/RU2611623C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. 1-[(4-фенил-2-пирролидон-1-ил)ацетил]таурат калия формулыобладающий ноотропной активностью и низкой токсичностью.2. Композиция для лечения и профилактики нарушений нервной системы, обладающая ноотропной активностью и низкой токсичностью, содержащая соединение по п 1, а также таурат калия и воду и характеризующаяся формулой.3. Композиция по п. 2, в которой мольное отношение 1-[(4-фенил-2-пирролидон-1-ил)ацетил]таурата калия, таурата калия и воды составляет 1:1:1.4. Способ получения соединения по п.1 и композиции по п.2, предусматривающийа) обработку 4-фенилпирролидона-2 избытком гранулированного KOH в ДМСО при нагревании, а затем избытком этилхлорацетата с получением карбэтоксиметилового эфира (2-оксо-4-фенилпирролидино)уксусной кислоты; иб) осуществление реакции карбэтоксиметилового эфира (2-оксо-4-фенилпирролидино)уксусной кислоты с тауратом калия.5. Способ лечения или профилактики нарушений нервной системы, предусматривающий введение нуждающемуся в этом пациенту терапевтически или профилактически эффективного количества композиции по п. 2.1.1 - [(4-phenyl-2-pyrrolidon-1-yl) acetyl] potassium taurate of the formula possessing nootropic activity and low toxicity. 2. A composition for the treatment and prevention of disorders of the nervous system, having nootropic activity and low toxicity, containing a compound according to claim 1, as well as potassium taurate and water and characterized by the formula. 3. The composition of claim 2, wherein the molar ratio of 1 - [(4-phenyl-2-pyrrolidon-1-yl) acetyl] potassium taurate, potassium taurate and water is 1: 1: 1.4. A method for producing a compound according to claim 1 and a composition according to claim 2, comprising: treating 4-phenylpyrrolidone-2 with an excess of granular KOH in DMSO by heating, and then with an excess of ethyl chloroacetate to give carbethoxymethyl ether (2-oxo-4-phenylpyrrolidino) acetic acid; ib) the reaction of carbethoxymethyl ether (2-oxo-4-phenylpyrrolidino) acetic acid with potassium taurate. 5. A method of treating or preventing disorders of the nervous system, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a composition according to claim 2.

Claims (5)

1. 1-[(4-фенил-2-пирролидон-1-ил)ацетил]таурат калия формулы1.1 - [(4-phenyl-2-pyrrolidon-1-yl) acetyl] potassium taurate of the formula
Figure 00000001
Figure 00000001
обладающий ноотропной активностью и низкой токсичностью.possessing nootropic activity and low toxicity.
2. Композиция для лечения и профилактики нарушений нервной системы, обладающая ноотропной активностью и низкой токсичностью, содержащая соединение по п 1, а также таурат калия и воду и характеризующаяся формулой2. A composition for the treatment and prevention of disorders of the nervous system, having nootropic activity and low toxicity, containing a compound according to claim 1, as well as potassium taurate and water and characterized by the formula
Figure 00000002
.
Figure 00000002
.
3. Композиция по п. 2, в которой мольное отношение 1-[(4-фенил-2-пирролидон-1-ил)ацетил]таурата калия, таурата калия и воды составляет 1:1:1.3. The composition according to p. 2, in which the molar ratio of 1 - [(4-phenyl-2-pyrrolidon-1-yl) acetyl] potassium taurate, potassium taurate and water is 1: 1: 1. 4. Способ получения соединения по п.1 и композиции по п.2, предусматривающий4. A method of obtaining a compound according to claim 1 and a composition according to claim 2, comprising а) обработку 4-фенилпирролидона-2 избытком гранулированного KOH в ДМСО при нагревании, а затем избытком этилхлорацетата с получением карбэтоксиметилового эфира (2-оксо-4-фенилпирролидино)уксусной кислоты; иa) treating 4-phenylpyrrolidone-2 with an excess of granular KOH in DMSO when heated, and then with an excess of ethyl chloroacetate to give carbethoxymethyl ether (2-oxo-4-phenylpyrrolidino) acetic acid; and б) осуществление реакции карбэтоксиметилового эфира (2-оксо-4-фенилпирролидино)уксусной кислоты с тауратом калия.b) the reaction of carbethoxymethyl ether (2-oxo-4-phenylpyrrolidino) acetic acid with potassium taurate. 5. Способ лечения или профилактики нарушений нервной системы, предусматривающий введение нуждающемуся в этом пациенту терапевтически или профилактически эффективного количества композиции по п. 2. 5. A method of treating or preventing disorders of the nervous system, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a composition according to claim 2.
RU2015148496A 2015-11-11 2015-11-11 4-phenyl pyrrolidinone-2 derivative, nootropic composition thereof, method for producing thereof and method preventive treatment of nervous system disorders RU2611623C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2015148496A RU2611623C2 (en) 2015-11-11 2015-11-11 4-phenyl pyrrolidinone-2 derivative, nootropic composition thereof, method for producing thereof and method preventive treatment of nervous system disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015148496A RU2611623C2 (en) 2015-11-11 2015-11-11 4-phenyl pyrrolidinone-2 derivative, nootropic composition thereof, method for producing thereof and method preventive treatment of nervous system disorders

Publications (2)

Publication Number Publication Date
RU2015148496A true RU2015148496A (en) 2016-05-10
RU2611623C2 RU2611623C2 (en) 2017-02-28

Family

ID=55959683

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015148496A RU2611623C2 (en) 2015-11-11 2015-11-11 4-phenyl pyrrolidinone-2 derivative, nootropic composition thereof, method for producing thereof and method preventive treatment of nervous system disorders

Country Status (1)

Country Link
RU (1) RU2611623C2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748419C2 (en) * 2017-02-20 2021-05-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Derivatives of 4-phenylpyrrolidone with anticonvulsant and nootropic activity as means of treating epilepsy and paroxysmal conditions
CN119504517A (en) * 2025-01-22 2025-02-25 浙江天启生化股份有限公司 A kind of preparation method of magnesium acetyl taurate

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741910C2 (en) * 2019-07-09 2021-01-29 Государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации Compounds having anti-ischemic, antianginal, cytoprotective properties, a method for production thereof and use thereof, a method of treating a neurodegenerative disease, a method of treating a psychic disorder
RU2711655C1 (en) * 2019-09-13 2020-01-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации Method for large-scale synthesis of potassium salt of 2-[2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamido]ethane sulphonic acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2437659C1 (en) * 2010-11-12 2011-12-27 Государственное образовательное учреждение высшего профессионального образования "Российский государственный педагогический университет им. А.И. Герцена" (РГПУ им. А.И. Герцена) Medication possessing antidepressive, anxiolytic and nootropic action
RU2440981C1 (en) * 2010-11-12 2012-01-27 Государственное образовательное учреждение высшего профессионального образования "Российский государственный педагогический университет им. А.И. Герцена" (РГПУ им. А.И. Герцена) Phenylhydrazide (4-phenyl-2-pyrrolidon-1-yl)-acetic acid, having nootropic, antidepressant and anxiolytic activity
RU2524651C1 (en) * 2013-06-20 2014-07-27 Общество С Ограниченной Ответственностью "Валента-Интеллект" Pharmaceutical composition in form of solution for injection and method for production thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748419C2 (en) * 2017-02-20 2021-05-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Derivatives of 4-phenylpyrrolidone with anticonvulsant and nootropic activity as means of treating epilepsy and paroxysmal conditions
CN119504517A (en) * 2025-01-22 2025-02-25 浙江天启生化股份有限公司 A kind of preparation method of magnesium acetyl taurate

Also Published As

Publication number Publication date
RU2611623C2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
JOP20210064A1 (en) Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
EA201071045A1 (en) COMPOUNDS OF OXADIAZOANTHRACENE FOR THE TREATMENT OF DIABETES
EA200971074A1 (en) ANTI-VIRUS CONNECTIONS
EA201200318A1 (en) Heterocyclic oximes
EA201490647A1 (en) DERIVATIVES OF BENZOTHIAZOL-6-LUCUS ACID AND THEIR APPLICATION FOR THE TREATMENT OF HIV INFECTION
EA201001159A1 (en) Condensed Heterocyclic Derivatives and Their Application
EA201071329A1 (en) ADAMANTANIA DIAMID DERIVATIVES AND THEIR APPLICATION
EA201390576A1 (en) ANTI-VIRUS COMPOUNDS
EA201391532A1 (en) Condensed Heterocyclic Compounds As Modulators of Ion Channels
EA201391720A1 (en) SUBSTITUTED DIOXOPIPERIDINYL-PHTHALIMIDE DERIVATIVES
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
EA201690899A1 (en) Oxazepins as modulators of ion channels
MX375261B (en) SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
EA201270492A1 (en) COMPOUNDS FOR THE TREATMENT OF DISLIPIDEMIC AND RELATED DISEASES
NZ726366A (en) Syk inhibitors
RU2015148496A (en) 4-Phenylpyrrolidinone-2 derivative containing its composition with nootropic activity, a method for their preparation and a method for the treatment or prevention of disorders of the nerve system
EA201890859A1 (en) PREVENTION, TREATMENT AND TREATMENT OF DEVELOPMENT OF DISEASE WITH THE APPLICATION OF THERAPEUTICALLY EFFECTIVE QUANTITIES OF ACTIVATED FATTY ACIDS
MX389965B (en) Pyrrolopyridine-aniline compounds for treatment of dermal disorders
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
EA201690972A1 (en) Condensed Heterocyclic Compounds As Modulators of Ion Channels
RU2010154144A (en) EXTERIOR FOR SKIN
MX383762B (en) GLUTARIMIDE DERIVATIVES, THEIR USE, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES.
MX2011009709A (en) Compounds for treating inflammation and pain.
MX2018014164A (en) INTERMEDIATES FOR SYNTHESIS OF BILIAR ACID DERIVATIVES, IN PARTICULAR, OF OBETICOLIC ACID.